CHE reports second-quarter results today against a backdrop of strong recent momentum and a striking shift in options positioning — the sharpest signal heading into the print.
Options traders have turned unusually call-heavy into the earnings event, but the put/call ratio jump tells a more complex story. The PCR more than doubled overnight to 0.069 on July 28, pushing over four standard deviations above its 20-day average of 0.034 — the most elevated defensive positioning relative to recent norms in the past year, even though the ratio itself remains low in absolute terms. The stock has earned that confidence to some degree: CHE is up 12% over the past month and closed at $517.63, a level well above the consensus analyst price target of $474. That gap between price and target means the Street's formal view is already stale relative to where the shares trade.
Short interest is not a meaningful headwind here. Bears hold roughly 4% of the free float — a moderate position that rose about 2.6% over the past week but remains near its month-ago level. Borrow conditions are extraordinarily loose, with availability at roughly 8,500% — more than fifteen times lent shares available versus shares borrowed — and a cost to borrow under 0.5%. There is no squeeze dynamic and no aggressive short-side conviction in the lending market.
The analyst debate centres on whether CHE's dual-segment model can sustain its recovery. Bulls point to VITAS, the country's largest hospice provider, as having genuine long-term volume growth ahead, with a 2026 rebound embedded in projections. The more bullish institutional holders appear to be adding: BlackRock lifted its stake to 10.1% of shares at last report, while River Road Asset Management added over 166,000 shares in the most recent quarter — a notable accumulation for a smaller active manager. Bears focus on Roto-Rooter, where a 520 basis-point EBITDA margin decline and weakening lead generation point to a business facing both cost pressure and softer consumer demand. Most recently, B of A raised its price target to $510 — still below current levels — while maintaining a Neutral rating, a signal that even the more constructive analyst voices see limited upside from here.
Insider activity adds a cautionary note. CEO Kevin McNamara has sold shares three times since March — totalling 5,500 shares at prices from $369 to $421 — well below today's $517 level. The net 90-day insider position reflects awards rather than open-market buying, meaning no executive has purchased into this rally. Past earnings reactions have been sharply positive: the April 2026 print drove a 10% one-day gain and held those gains through five days. The print today will test whether VITAS volume growth and Roto-Rooter margin stabilisation can justify a share price that has run well past what most analysts are willing to formally defend.
See the live data behind this article on ORTEX.
Open CHE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
